Satellos Bioscience Inc. MSLE
8.70
(0.01)
(0.11%)
as of 25 Sep
- Market cap
- $184.8M
- P/E
- 0.0×
Follow MSLE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
9.94 | 6.84 | 15.48 | 10.68 | |
Current Ratio |
10.70 | 7.77 | 16.48 | 11.22 | |
Net Debt/EBITDA |
5.80 | 3.62 | 6.96 | 5.08 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.71 | 0.99 | 0.98 | 0.69 | |
Capex/Depreciation |
(1.00) | 0.00 | (4.00) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.30) | (0.50) | (0.52) | (0.39) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.50) | (0.52) | (0.39) | |
Cash per Share |
2.48 | 1.90 | 3.79 | 2.97 | |
Shareholders Equity per Share |
2.44 | 1.90 | 3.83 | 2.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.44 | 1.90 | 3.83 | 2.88 | |
Free Cash Flow |
(4.13) | (7.26) | (9.59) | (8.03) | |
Working Capital |
33.99 | 27.78 | 70.66 | 59.90 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
33.99 | 27.78 | 70.66 | 59.90 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Receivables |
0.17 | 0.40 | 0.53 | 0.48 | |
Average Payables |
3.08 | 3.84 | 3.63 | 4.32 | |
Average Assets |
27.62 | 41.32 | 59.80 | 53.44 | |
Average Common Equity |
24.55 | 37.47 | 56.17 | 49.13 |
Columns are period end dates